Please login to the form below

Not currently logged in
Email:
Password:

Roche sues Dr Reddy's over Boniva for osteoporosis

Roche is taking legal action against Indian generic manufacturer Dr Reddy's Laboratories in the US to prevent the Indian's pharma group from marketing a generic version of osteoporosis drug Boniva

Swiss-based pharmaceutical company Roche is taking legal action against Indian generic manufacturer Dr Reddy's Laboratories in the US to prevent the Indian's pharma group from marketing a generic version of Roche's osteoporosis drug Boniva (ibandronate).

The complaint was filed on 20 September in a New Jersey court. Roche says that Boniva is covered by patents running from 2012 to 2023.

In a statement, Roche said: "This action arises because of Dr Reddy's efforts to gain approval from the FDA to market a generic copy of Roche's Boniva once-monthly drug product prior to the expiration of Roche's patent rights covering it."

Earlier in September, Roche initiated legal action against Israel-headquartered generics giant Teva Pharmaceutical's move to enter the US market with a Boniva copy.

Boniva, which is sold under the name of Bonviva in the EU, racked up sales of CHF 488m in FY06.

25th September 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics